You are here: Home » Companies » News
Business Standard

Shocked at Patanjali's 'blatant lie of WHO certification', says IMA

The launch was attended by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

indian medical association | Patanjali | WHO

Ruchika Chitravanshi  |  New Delhi 

Coronil launch
Yoga guru Ramdev flanked by Union ministers Harsh Vardhan (left) and Nitin Gadkari at last week’s launch of Coronil PTI

The (IMA) has expressed shock at the “blatant lie of certification” of Patanjali’s Coronil and questioned Health Minister Harsh Vardhan for promoting the drug.

In a strongly worded statement, the IMA asked Vardhan the ethics of such endorsement and release of “such falsely fabricated and unscientific product to the people of the whole country”.

Yoga guru Ramdev had on Friday released a paper by Haridwar-based Research Institute on Coronil, which it claimed to be the “first evidence-based ayurvedic medicine” against the disease.

“Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the certification scheme,” said in a statement.

The launch was attended by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

Following this, World Health Organization South-East Asia said in a tweet: “@has not reviewed or certified the effectiveness of any traditional medicine for the treatment #Covid19.” The company had issued a clarification, just ahead of the WHO’s tweet: “We want to clarify to avoid confusion that our WHO GMP compliant CoPP certificate to Coronil is issued by DCGI... It is clear that WHO does not approve or disapprove any drugs. WHO works for building a better, healthier future for people all over the world.”

IMA has sought details of the timeline of clinical trials of the Coronil drug from the health minister. “Can you clarify the number of patients in the double blind or single blind trials of this so-called anti-corona product promoted by you? On what ground was it approved by the DCGI as was announced in your presence?” the IMA statement reads.

Referring to Ramdev’s statement that modern medicine was medical terrorism, IMA said in reply: “Being the health minister of the country and a modern medicine doctor, can you clarify the highly objectionable and instigative statement by Ramdev.”

IMA also said: “The country needs an explanation from the minister. The will also write to the National Medical Commission for seeking suo moto explanation for his blatant disrespect to the code of conduct of Medical Council of India.”

Quoting the code of conduct under the Indian Medical Council Act, the IMA statement said no doctor can promote any drug, for compensation or otherwise. “Dispensing by a physician of a secret remedial agents of which he does not know the composition, or the manufacture or promotion of their use is unethical and as such prohibited.”

Ramdev-led Ayurved had launched Coronil on June 23. Patanjali CEO Acharya Balkrishna claimed that the medicine could cure Covid-19 patients within 5-14 days.

At the time of the launch of the drug, the AYUSH ministry had asked the company to stop ads for the drug until the issue had been examined. The ministry had also sought a detailed report on composition, testing and other data for the drug. The Centre had barred the firm from advertising the products after Ramdev said they cured 280 patients within days in trials. Coronil was then passed as an “immuno-booster” only.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 22 2021. 23:35 IST